Clinical trials in nuclear medicine. Sorted by date of last update.
Lu-177-DOTA-EB-TATE in Adult Patients with Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Phase 1
Last update: December 29
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
Phase 2
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used with Targeted Radiation-based Treatment (Lutetium Lu-177 Dotatate), Compared to Lutetium Lu-177 Dotatate Alone for Metastatic Neuroendocrine Tumors
Testing Lutetium Lu-177 Dotatate in Patients with Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Comparing Retreatment of Lu-177-DOTATATE PRRT versus the Usual Treatment in Patients with Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
Study to Assess [Lu-177]Lu-PSMA-R2 (AAA602) and [Ac-225]Ac-PSMA-R2 (AAA802) in Participants with PSMA-positive HRLPC (NeoPSMA)
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones
Prospective Evaluation of Imaging Response Biomarkers During [Lu-177]Lu-PSMA in Metastatic Castration-resistant Prostate Cancer (Ga-68-PSMA)
N/A
Last update: December 26
Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma
Early Phase 1
Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90